A number of other equities analysts have also weighed in on IDYA. Wedbush lifted their price objective on IDEAYA Biosciences to $30.00 in a research note on Wednesday, December 14th. Robert W. Baird lifted their price objective on IDEAYA Biosciences from $18.00 to $24.00 and gave the company an outperform rating in a research note on Friday, November 18th. Citigroup initiated coverage on IDEAYA Biosciences in a research note on Thursday, October 27th. They set a buy rating and a $26.00 price objective for the company. Finally, Capital One Financial initiated coverage on IDEAYA Biosciences in a research note on Wednesday, December 28th. They set an overweight rating and a $29.00 price objective for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $28.25.
IDEAYA Biosciences Price Performance
Shares of IDYA stock opened at $16.37 on Monday. The firm has a market capitalization of $787.61 million, a price-to-earnings ratio of -12.04 and a beta of 0.96. The business has a fifty day moving average of $17.46 and a 200 day moving average of $15.21. IDEAYA Biosciences has a 1 year low of $8.14 and a 1 year high of $19.14.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in IDYA. JPMorgan Chase & Co. raised its position in IDEAYA Biosciences by 5.0% in the second quarter. JPMorgan Chase & Co. now owns 21,055 shares of the company’s stock valued at $291,000 after purchasing an additional 997 shares during the period. Nisa Investment Advisors LLC purchased a new position in IDEAYA Biosciences in the second quarter valued at about $25,000. Rhumbline Advisers increased its holdings in IDEAYA Biosciences by 4.8% in the first quarter. Rhumbline Advisers now owns 39,982 shares of the company’s stock valued at $447,000 after buying an additional 1,835 shares in the last quarter. AXA S.A. increased its holdings in IDEAYA Biosciences by 0.4% in the third quarter. AXA S.A. now owns 429,118 shares of the company’s stock valued at $6,402,000 after buying an additional 1,870 shares in the last quarter. Finally, Virtus ETF Advisers LLC increased its holdings in IDEAYA Biosciences by 26.4% in the second quarter. Virtus ETF Advisers LLC now owns 9,088 shares of the company’s stock valued at $125,000 after buying an additional 1,896 shares in the last quarter. 94.20% of the stock is currently owned by institutional investors and hedge funds.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
- Get a free copy of the StockNews.com research report on IDEAYA Biosciences (IDYA)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.